Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

Clare L Collins1, Andrew J Pollard

  • 1Department of Paediatrics, University of Oxford, John Radcliffe Hospital, UK. clare.collins@paediatrics.ox.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|August 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Nature communications·2022
Same author

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Infection and immunity·2022
Same author

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Human vaccines & immunotherapeutics·2022
Same author

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

The Journal of infection·2022
Same author

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

JCI insight·2022
Same author

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

JCI insight·2022
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Meningococcal vaccines target serogroups A, C, Y, and W135, but an effective serogroup B vaccine for Neisseria meningitidis remains a challenge for child health.

Area of Science:

  • Microbiology
  • Vaccinology
  • Pediatric Infectious Diseases

Background:

  • Neisseria meningitidis is a major cause of infectious death in children under five in industrialized nations.
  • Five serogroups (A, B, C, Y, W135) cause the majority of meningococcal disease cases.
  • Early meningococcal vaccines (whole-cell, exotoxin, polysaccharide) had limitations, particularly in young children.

Purpose of the Study:

  • To review the historical development and current challenges in meningococcal vaccine research.
  • To highlight the efficacy of protein-polysaccharide conjugate vaccines against specific serogroups.
  • To identify the ongoing difficulties in developing a serogroup B vaccine.

Main Methods:

  • Review of historical vaccine development milestones.

Related Experiment Videos

  • Analysis of polysaccharide and conjugate vaccine immunogenicity and efficacy data.
  • Discussion of challenges in serogroup B vaccine development.

    • Main Results:

    • Polysaccharide vaccines are available for serogroups A, C, Y, and W135, but show limited efficacy in young children.
    • Protein-polysaccharide conjugate vaccines improve immunogenicity and offer protection against serogroups A, C, Y, and W135 in early childhood.
    • An effective vaccine against serogroup B remains a significant hurdle.

    Conclusions:

    • While conjugate vaccines have advanced protection against several serogroups, a universal meningococcal vaccine, especially for serogroup B, is still needed.
    • Further research is critical to overcome the challenges in developing a broadly protective and effective meningococcal vaccine for all age groups.
    • Addressing the serogroup B vaccine gap is crucial for reducing childhood mortality from meningococcal disease.